Sanofi backs annual guidance as Dupixent sales surge over 40% in Q1

2023-04-27

·Firstwordpharma

临床1期临床2期财报

Headline results for the first quarter:

Prescription drug sales: €8.7 billion ($9.6 billion), up 4.9%

Overall revenue: €10.2 billion ($11.3 billion; forecasts of €10.5 billion), up 5.7%

Profit: €2 billion ($2.2 billion), down 0.7%

Note: All changes are versus the prior-year period unless otherwise stated

What the company said:

"We have started 2023 with strong results, delivering double-digit sales growth across our specialty care, vaccines and consumer healthcare businesses," remarked CEO Paul Hudson. The executive added "Dupixent continues its compelling performance and is on track to achieve its €10 billion sales objective for this year."

Other results:

Specialty care unit: €4.3 billion, up 20.2%

Dupixent: €2.3 billion, up 43.5%

Aubagio: €419 million, down 14.7%

Alprolix: €125 million, up 15.7%

Eloctate: €118 million, down 14.5%

General medicines unit: €3.3 billion, down 12.4%

Lantus: €447 million, down 33.4%

Toujeo: €289 million, up 5.5%

Praluent: €98 million, up 42%

Vaccines division: €1.2 billion, up 14.4%

Consumer healthcare: €1.5 billion, up 10.4%

Sales in China: €755 million, down 14% on a constant exchange rate (CER) basis

Looking ahead:

Sanofi continues to expect business earnings per share to grow in the low-single digits this year on a CER basis, excluding negative currency effects of between 5.5% and 6.5%. The company had previously flagged a negative currency impact in the range of 3.5% to 4.5%.

Pipeline updates:

Sanofi disclosed that development of the topical BTK inhibitor BTK inhibitor atuzabrutinib has been discontinued due to efficacy and sub-optimal pharmacokinetics from a Phase II study in patients with mild-to-moderate atopic dermatitis. The company added that a mid-stage trial of subcutaneous Sarclisa in adults with warm autoimmune haemolytic anaemia was also halted, citing preliminary results and portfolio prioritisation.